Literature DB >> 5571498

Diuretics in chronic renal disease: a study of high dosage frusemide.

M E Allison, A C Kennedy.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 5571498     DOI: 10.1042/cs0410171

Source DB:  PubMed          Journal:  Clin Sci        ISSN: 0009-9287            Impact factor:   6.124


× No keyword cloud information.
  21 in total

Review 1.  Diuretics: mechanism of action and clinical application.

Authors:  D L Davies; G M Wilson
Journal:  Drugs       Date:  1975       Impact factor: 9.546

2.  Editorial: Picking a diuretic.

Authors: 
Journal:  Br Med J       Date:  1975-06-07

Review 3.  Clinical pharmacokinetics of frusemide.

Authors:  R E Cutler; A D Blair
Journal:  Clin Pharmacokinet       Date:  1979 Jul-Aug       Impact factor: 6.447

4.  Continuous infusion of frusemide in refractory oedema [proceedings].

Authors:  J M Gray; D A Henry; D H Lawson; W J Tilstone; H J Longman
Journal:  Br J Pharmacol       Date:  1978-11       Impact factor: 8.739

5.  Management of refractory oedema.

Authors: 
Journal:  Br Med J       Date:  1979-01-20

6.  Pharmacokinetics/pharmacodynamics of furosemide in man: a review.

Authors:  L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1979-02

7.  Pathophysiology of experimental glomerulonephritis in rats.

Authors:  M E Allison; C B Wilson; C W Gottschalk
Journal:  J Clin Invest       Date:  1974-05       Impact factor: 14.808

8.  Furosemide disposition in patients on CAPD.

Authors:  U Martin; R J Winney; L F Prescott
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

9.  Diuretic action of bumetanide in advanced chronic renal insufficiency.

Authors:  K J Berg; A Tromsdal; T E Wideroe
Journal:  Eur J Clin Pharmacol       Date:  1976-02-06       Impact factor: 2.953

10.  Oral piretanide in chronic renal failure.

Authors:  I S Henderson; T J Beattie; A C Kennedy; S L Dombey
Journal:  Br J Clin Pharmacol       Date:  1982-12       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.